MetLife is one of the largest life insurers in the US by assets and provides a variety of life insurance and annuity products... Show more
MetLife's medium-term trajectory is anchored in its "New Frontier" strategy, a five-year plan running through 2029 built on four priorities: extending leadership in U.S. Group Benefits, capitalizing on its retirement platform, accelerating growth in asset management, and expanding in high-growth international markets. The company is the No. 1 U.S. group benefits provider and holds a market-leading life insurance position in Latin America, with deep franchises in Japan, Korea, Mexico, Brazil, India, and China.
A defining element of the strategy is the shift toward capital-light, fee-based earnings. The December 2025 acquisition of PineBridge Investments lifted assets under management (AUM) at MetLife Investment Management to about $742 billion, reinforcing management's long-term aspiration of reaching $1 trillion in AUM. This diversification reduces reliance on more volatile U.S. individual underwriting and supports a target of 15% to 17% adjusted return on equity (ROE), a metric that measures profitability relative to shareholder capital. Management has also signaled that technology modernization, including more than $3 billion in recent investments, is enabling faster claims processing and AI-assisted underwriting, which it frames as both a cost lever and a growth enabler.
The next earnings report, due in early November 2026, is the most immediate catalyst, with investors focused on whether adjusted earnings per share (EPS) growth remains in the double digits and whether the favorable group-life mortality trend persists. Management has guided to double-digit adjusted EPS growth and 15% to 17% adjusted ROE for 2026, alongside variable investment income of roughly $1.6 billion.
Beyond earnings, several catalysts could shape sentiment. The integration of PineBridge and the realization of its cost synergies will be closely watched, as will the pace of PRT origination and U.K. longevity reinsurance deals, which management describes as "lumpy" but structurally attractive. Capital allocation remains a focal point, with a recently announced $3 billion share repurchase program and a dividend history spanning a decade. On the analyst front, consensus has turned more constructive: S&P Global's poll shows a "Buy" rating with an average price target near $108, while firms including TD Cowen, J.P. Morgan, Wells Fargo, Barclays, and Bank of America raised targets in September and October 2026, and Piper Sandler upgraded the stock to Overweight.
MetLife's earnings are closely tied to the interest-rate environment and credit markets. Higher-for-longer rates tend to support investment income on its fixed-income portfolio, while lower rates can pressure reinvestment yields and long-duration liabilities. Variable investment income from private equity and venture capital adds another layer of macro sensitivity, as gains there fluctuate with initial public offering activity and broader risk appetite.
Demographic trends provide a structural tailwind: aging populations across developed markets are driving demand for annuities, longevity reinsurance, and pension de-risking solutions. The PRT market, estimated at more than $1.5 trillion of well-funded pension liabilities, remains a key opportunity. At the same time, inflationary pressure on healthcare and dental costs can affect group benefits margins, and currency swings in Japan, Korea, and Latin America can distort reported results. Regulatory scrutiny, including industry-wide reviews in Japan, is an additional factor management continues to monitor.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. The tool is built to surface developing trends, evaluate potential breakouts or reversals, and support research across a broad universe of tradable instruments, with searchable prediction categories and historical context for added perspective. For investors monitoring MetLife's market positioning and growth catalysts, the engine offers a data-driven way to complement fundamental analysis and track evolving price signals as new information emerges.
Looking toward 2026 and beyond, MetLife's outlook hinges on whether its capital-light model can sustain double-digit EPS growth while improving efficiency. Management has committed to a 100 basis point reduction in the direct expense ratio over the New Frontier period, targeting roughly 11.3% by 2029, with AI and process automation central to that goal. Margin sustainability in Group Benefits will depend on whether favorable working-age mortality trends persist or normalize, a dynamic management expects to unfold gradually over years rather than quarters.
Longer-term, the push toward $1 trillion in AUM and a 32% operating margin at MetLife Investment Management by 2029 represents a structural expansion opportunity. International markets such as Japan, Korea, Mexico, and Brazil offer above-market growth potential, while the Chariot Re sidecar and flow reinsurance initiatives provide added capital flexibility. Competitive threats include pricing pressure in group benefits, regulatory changes, and rising technology costs. Consensus expectations reflect measured optimism, with analysts generally maintaining Buy or Overweight ratings and a higher average price target than a year ago, though any softening in spreads, investment income, or mortality favorability could prompt a reassessment of that outlook.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MET has been closely correlated with PRU. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if MET jumps, then PRU could also see price increases.
a provider of insurance and financial services and also function as bank holding company
Industry LifeHealthInsurance
MET saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 27, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In 32 of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 60%.
The 10-day RSI Indicator for MET moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In 25 of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 68 cases where MET's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
MET broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on MET as a result. In 47 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
MET moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MET crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +2.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MET advanced for three days, in 224 of 344 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 153 of 283 cases where MET Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 21 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 28 (best 1 - 100 worst), indicating outstanding price growth. MET’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MET's P/B Ratio (2.338) is slightly higher than the industry average of (1.339). P/E Ratio (19.190) is within average values for comparable stocks, (19.974). Projected Growth (PEG Ratio) (0.506) is also within normal values, averaging (0.463). Dividend Yield (0.023) settles around the average of (0.047) among similar stocks. P/S Ratio (0.824) is also within normal values, averaging (1.303).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.